Nektar Therapeutics (NKTR) CEO Howard W. Robin Sells 83,333 Shares

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction on Monday, October 9th. The shares were sold at an average price of $24.20, for a total value of $2,016,658.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Nektar Therapeutics (NKTR) opened at 23.27 on Wednesday. The company’s market cap is $3.64 billion. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $25.02. The stock’s 50 day moving average price is $21.98 and its 200-day moving average price is $20.41.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.36) EPS. On average, analysts forecast that Nektar Therapeutics will post ($0.98) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/11/nektar-therapeutics-nktr-ceo-howard-w-robin-sells-83333-shares.html.

Several research analysts have recently weighed in on NKTR shares. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, August 18th. BidaskClub raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. HC Wainwright assumed coverage on Nektar Therapeutics in a report on Monday, August 7th. They issued a “buy” rating and a $31.00 price objective for the company. Zacks Investment Research lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.80.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in shares of Nektar Therapeutics by 180,432.9% in the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock worth $470,234,000 after acquiring an additional 20,024,448 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Nektar Therapeutics during the second quarter worth $34,661,000. PointState Capital LP grew its stake in shares of Nektar Therapeutics by 281.7% during the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after purchasing an additional 1,277,500 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Nektar Therapeutics by 4.9% during the first quarter. Vanguard Group Inc. now owns 13,607,980 shares of the biopharmaceutical company’s stock worth $319,379,000 after purchasing an additional 634,700 shares in the last quarter. Finally, FMR LLC grew its stake in shares of Nektar Therapeutics by 42.4% during the first quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock worth $45,711,000 after purchasing an additional 580,341 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Nektar Therapeutics (NKTR) opened at 23.27 on Wednesday. The company’s market cap is $3.64 billion. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $25.02. The stock’s 50 day moving average price is $21.98 and its 200-day moving average price is $20.41.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.36) EPS. On average, analysts forecast that Nektar Therapeutics will post ($0.98) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/11/nektar-therapeutics-nktr-ceo-howard-w-robin-sells-83333-shares.html.

Several research analysts have recently weighed in on NKTR shares. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, August 18th. BidaskClub raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. HC Wainwright assumed coverage on Nektar Therapeutics in a report on Monday, August 7th. They issued a “buy” rating and a $31.00 price objective for the company. Zacks Investment Research lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Finally, William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.80.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in shares of Nektar Therapeutics by 180,432.9% in the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock worth $470,234,000 after acquiring an additional 20,024,448 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Nektar Therapeutics during the second quarter worth $34,661,000. PointState Capital LP grew its stake in shares of Nektar Therapeutics by 281.7% during the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after purchasing an additional 1,277,500 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Nektar Therapeutics by 4.9% during the first quarter. Vanguard Group Inc. now owns 13,607,980 shares of the biopharmaceutical company’s stock worth $319,379,000 after purchasing an additional 634,700 shares in the last quarter. Finally, FMR LLC grew its stake in shares of Nektar Therapeutics by 42.4% during the first quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock worth $45,711,000 after purchasing an additional 580,341 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.